Hana Pharm Co Ltd (293480) - Total Assets
Based on the latest financial reports, Hana Pharm Co Ltd (293480) holds total assets worth ₩446.69 Billion KRW (≈ $302.72 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hana Pharm Co Ltd - Total Assets Trend (2016–2025)
This chart illustrates how Hana Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see 293480 market cap for the company's overall valuation and market capitalisation.
Hana Pharm Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Hana Pharm Co Ltd's total assets of ₩446.69 Billion consist of 28.2% current assets and 71.8% non-current assets. Review Hana Pharm Co Ltd (293480) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.4% |
| Accounts Receivable | ₩40.21 Billion | 9.6% |
| Inventory | ₩58.07 Billion | 13.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩18.00 Billion | 4.3% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Hana Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 293480 live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hana Pharm Co Ltd's current assets represent 28.2% of total assets in 2025, a decrease from 52.8% in 2016.
- Cash Position: Cash and equivalents constituted 2.4% of total assets in 2025, up from 1.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 1.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 13.9% of total assets.
Hana Pharm Co Ltd Competitors by Total Assets
Key competitors of Hana Pharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥22.22 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC
|
Turkey | TL70.69 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥10.50 Billion |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728
|
China | CN¥2.33 Billion |
Hana Pharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.96 | 1.97 | 4.75 |
| Quick Ratio | 0.98 | 0.92 | 3.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩61.65 Billion | ₩52.44 Billion | ₩114.44 Billion |
Hana Pharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hana Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.45 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 9.5% |
| Total Assets | ₩418.14 Billion |
| Market Capitalization | $99.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hana Pharm Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hana Pharm Co Ltd's assets grew by 9.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hana Pharm Co Ltd (2016–2025)
The table below shows the annual total assets of Hana Pharm Co Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩418.14 Billion ≈ $283.37 Million |
+9.46% |
| 2024-12-31 | ₩382.01 Billion ≈ $258.88 Million |
+9.65% |
| 2023-12-31 | ₩348.39 Billion ≈ $236.10 Million |
+0.70% |
| 2022-12-31 | ₩345.96 Billion ≈ $234.46 Million |
+13.99% |
| 2021-12-31 | ₩303.50 Billion ≈ $205.68 Million |
+9.73% |
| 2020-12-31 | ₩276.58 Billion ≈ $187.43 Million |
+5.15% |
| 2019-12-31 | ₩263.03 Billion ≈ $178.25 Million |
+8.52% |
| 2018-12-31 | ₩242.38 Billion ≈ $164.26 Million |
+71.23% |
| 2017-12-31 | ₩141.55 Billion ≈ $95.93 Million |
+23.53% |
| 2016-12-31 | ₩114.59 Billion ≈ $77.66 Million |
-- |
About Hana Pharm Co Ltd
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and an… Read more